![Alan R. Engbring](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karriereverlauf von Alan R. Engbring
Ehemalige bekannte Positionen von Alan R. Engbring
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Investor Relations Kontakt | 01.07.1996 | 01.11.2013 |
Public Communications Contact | 01.07.1996 | 01.11.2013 | |
HISTOGEN INC. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Investor Relations Contact | 2 |
Public Communications Contact | 2 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Conatus Pharmaceuticals, Inc.
![]() Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Alan R. Engbring
- Erfahrung